Scynexis (SCYX)

Executive Summary

Scynexis is a commercial-stage biotechnology company focused on antifungal therapies, highlighted by its approved product BREXAFEMME (ibrexafungerp) for vulvovaginal candidiasis, partnered with GSK. The company has completed Phase 3 trials for ibrexafungerp in invasive candidiasis, positioning it for potential label expansion. Despite a strong clinical profile and a novel mechanism (fungerps), commercial adoption has been modest, and the company faces competition from established antifungals. Scynexis is also exploring ibrexafungerp for other indications such as aspergillosis and coccidioidomycosis. With a market cap of ~$77M, the stock reflects uncertainty around revenue growth and regulatory milestones. Key upcoming events include potential FDA submission for invasive candidiasis, sales trajectory from the GSK partnership, and pipeline progress for next-generation candidates.

Upcoming Catalysts (preview)

• H2 2026FDA sNDA submission for ibrexafungerp in invasive candidiasis (with or without priority review)70% success
• Q3 2026Quarterly BREXAFEMME sales updates and GSK partnership milestones80% success
• TBDInitiation or data readout for next-generation antifungal candidate (SCY-247 or similar)50% success